CAS 179324-69-7
:Bortezomibe
Descrição:
Bortezomibe é um inibidor do proteassoma utilizado principalmente no tratamento do mieloma múltiplo e certos tipos de linfoma. É um composto sintético que pertence à classe dos derivados do ácido bórico. A fórmula química de Bortezomibe é C19H25BoroN4O4, e apresenta um átomo de boro que desempenha um papel crucial em seu mecanismo de ação, que envolve a inibição do proteassoma, um complexo celular responsável pela degradação de proteínas ubiquitinadas. Essa inibição leva ao acúmulo de fatores pró-apoptóticos e reguladores do ciclo celular, induzindo, em última análise, a apoptose em células cancerosas. Bortezomibe é administrado por injeção intravenosa ou subcutânea e é conhecido por seus efeitos colaterais, que podem incluir neuropatia periférica, problemas gastrointestinais e toxicidades hematológicas. Sua farmacocinética envolve rápida absorção e distribuição, com uma meia-vida que permite esquemas de dosagem eficazes. No geral, Bortezomibe representa um avanço significativo na terapia direcionada ao câncer, mostrando o potencial de pequenas moléculas no tratamento de malignidades hematológicas.
Fórmula:C19H25BN4O4
InChI:InChI=1S/C19H25BN4O4/c1-13(2)10-17(20(27)28)24-18(25)15(11-14-6-4-3-5-7-14)23-19(26)16-12-21-8-9-22-16/h3-9,12-13,15,17,27-28H,10-11H2,1-2H3,(H,23,26)(H,24,25)/t15-,17-/m0/s1
Chave InChI:InChIKey=GXJABQQUPOEUTA-RDJZCZTQSA-N
SMILES:[C@H](CC1=CC=CC=C1)(C(N[C@@H](CC(C)C)B(O)O)=O)NC(=O)C=2C=NC=CN2
Sinónimos:- B-[(1R)-3-Methyl-1-[[(2S)-1-oxo-3-phenyl-2-[(2-pyrazinylcarbonyl)amino]propyl]amino]butyl]boronic acid
- Boronic acid, B-[(1R)-3-methyl-1-[[(2S)-1-oxo-3-phenyl-2-[(2-pyrazinylcarbonyl)amino]propyl]amino]butyl]-
- Boronic acid, [(1R)-3-methyl-1-[[(2S)-1-oxo-3-phenyl-2-[(pyrazinylcarbonyl)amino]propyl]amino]butyl]-
- Boronic acid, [3-methyl-1-[[1-oxo-3-phenyl-2-[(pyrazinylcarbonyl)amino]propyl]amino]butyl]-, [S-(R*,S*)]-
- Bortezomib for research
- Bortizomib
- Brotezamide
- Dpba
- Ldp 341
- Mg 341
- Mln 341
- N-[(1R)-1-(dihydroxyboranyl)-3-methylbutyl]-Nalpha-(pyrazin-2-ylcarbonyl)-L-phenylalaninamide
- N-[(1S)-1-(dihydroxyboranyl)-3-methylbutyl]-Nalpha-(pyrazin-2-ylcarbonyl)-D-phenylalaninamide
- NSC 681239
- PS 341 (pharmaceutical)
- Ps 314
- Ps 341
- Radiciol
- Velcade
- Ver mais sinónimos
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
13 produtos.
Bortezomib
CAS:Fórmula:C19H25BN4O4Pureza:>98.0%(HPLC)Cor e Forma:White to Almost white powder to crystalPeso molecular:384.24Bortezomib, 98%
CAS:<p>Bortezomib, 179324-69-7, is a peptidic boronic acid analog and antineoplastic agent which turns off cell signaling pathways through 26S proteasome inhibition. Learn more.</p>Fórmula:C19H25BN4O4Pureza:98%Cor e Forma:Powder or crystals or crystalline powder, White to off-whitePeso molecular:384.24Boronic acid, B-[(1R)-3-methyl-1-[[(2S)-1-oxo-3-phenyl-2-[(2-pyrazinylcarbonyl)amino]propyl]amino]butyl]-
CAS:Fórmula:C19H25BN4O4Pureza:98%Cor e Forma:SolidPeso molecular:384.2372Bortezomib
CAS:Fórmula:C19H25BN4O4Pureza:≥ 98.0%Cor e Forma:White to off-white powder or solidPeso molecular:384.24Bortezomib
CAS:BortezomibFórmula:C19H25BN4O4Pureza:98% (nmr) (Typical Value in Batch COA)Cor e Forma: white solidPeso molecular:384.24g/molBortezomib
CAS:Bortezomib (LDP 341) is a 20S proteasome inhibitor (Ki=0.6 nM) that is reversible and selective.Fórmula:C19H25BN4O4Pureza:97.79% - >99.99%Cor e Forma:Yellow SolidPeso molecular:384.24Bortezomib-D8 (Major)
CAS:Produto Controlado<p>Applications Labelled Bortezomib, which the first proteasome inhibitor to be approved by the US FDA for multiple myeloma, a blood cancer. A reversible inhibitor of the 26S proteasome-a barrel-shaped multiprotein particle found in the nucleus and cytosol of all eukaryotic cells.d6-3%d7-10%d8-86%<br> Not a dangerous good if item is equal to or less than 1g/ml and there is less than 100g/ml in the package<br>References Nawrocki, S.T., et al: Cancer Research, 65, 11510 (2005)<br></p>Fórmula:C19H17D8BN4O4Cor e Forma:Off-WhitePeso molecular:392.29Bortezomib
CAS:Produto Controlado<p>Stability Hygroscopic and Moisture Sensitive<br>Applications Bortezomib is the first proteasome inhibitor to be approved by the US FDA for multiple myeloma, a blood cancer. A reversible inhibitor of the 26S proteasome-a barrel-shaped multiprotein particle found in the nucleus and cytosol of all eukaryotic cells. Targets the ubiquitin-proteasome pathway.<br> Not a dangerous good if item is equal to or less than 1g/ml and there is less than 100g/ml in the package<br>References Nawrocki, S.T., et al: Cancer Research, 65, 11510 (2005); Drahl C.: Chem. and Eng. News, 87, 41 (2009);<br></p>Fórmula:C19H25BN4O4Cor e Forma:White To Off-WhitePeso molecular:384.24Bortezomib - Bio-X ™
CAS:<p>Bortezomib is a selective and reversible inhibitor of the multicatalytic 26S proteasome. The inhibition of protein breakdown affects several metabolic pathways and leads to cell death. The compound is effective in treating t-cell lymphomas and multiple myeloma because it prevents the binding of myeloma cells to bone marrow stroma and inhibits osteoclast differentiation.</p>Fórmula:C19H25BN4O4Pureza:Min. 95%Cor e Forma:PowderPeso molecular:384.24 g/molBortezomib
CAS:<p>Selective and reversible inhibitor of the multicatalytic 26S proteasome. The inhibition of protein breakdown affects several metabolic pathways and leads to cell death. The compound is effective in treating multiple myeloma because it prevents the binding of myeloma cells to bone marrow stroma and inhibits osteoclast differentiation.</p>Fórmula:C19H25BN4O4Pureza:Min. 95%Cor e Forma:White PowderPeso molecular:384.24 g/mol
![Boronic acid, B-[(1R)-3-methyl-1-[[(2S)-1-oxo-3-phenyl-2-[(2-pyrazinylcarbonyl)amino]propyl]amino]…](/_next/image/?url=https%3A%2Fstatic.cymitquimica.com%2Fproducts%2FIN%2Fthumb%2FDA0026XG.jpg&w=3840&q=75)
